


IN THE CLAIMS

1. (currently amended): A compound of formula I,



wherein X represents an ~~optionally substituted aryl or heteroaryl group~~ or an optionally substituted amide, amine or sulfonamide group, which latter three groups are connected to the indole ring through their nitrogen atom;

Y represents a carboxylic acid, a carboxylic acid ester, a carboxylic acid amide, a hydroxamic acid, a hydroxamic acid ester or hydroxymethyl;

Z ~~represents a spacer group~~ comprises a C₁₋₈ alkylene or a C₂₋₈ heteroalkylene chain;

R¹ represents an optionally substituted aryl or heteroaryl group;
 one of the groups R², R³, R⁴ and R⁵ represents an optionally substituted aryl or heteroaryl group and the other groups R², R³, R⁴ and R⁵ are independently selected from hydrogen, G¹, an aryl group, a heteroaryl group (which latter two groups are optionally substituted by one or more substituents selected from A), C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl (which latter five groups are optionally substituted by one or more substituents selected from G¹ and/or Q¹); and/or

b) any two other groups which are adjacent to each other are optionally linked to form, along with two atoms of the essential benzene ring in the compound of formula I, a 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

A represents:

l) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B;

II) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₈ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G¹ and/or Q¹; or

III) a G¹ group; or

IV) two adjacent A substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two A substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

G¹ represents, on each occasion when mentioned above, halo, cyano, -N₃, -N₂, -ONO₂ or -A¹-R¹⁰.

wherein A¹ represents a single bond or a spacer group selected from -C(Q²)A²-, -S(O)_nA³-, -N(R¹¹)A⁴-, -OA⁵- and -S-, in which:

A² represents A⁶ or -S-;

A³ represents A⁶;

A⁴ represents A⁷, -C(Q²)N(A¹¹)C(Q²)N(R¹¹)-, -C(Q²)N(A¹¹)C(Q²)O-,
C(Q²)N(A¹¹)S(O)_nN(R¹¹)-, -C(Q²)S-, -S(O)_nN(R¹¹)C(Q²)N(R¹¹)-, -S(O)_nN(R¹¹)C(Q²)O-,
-S(O)_nN(R¹¹)S(O)_nN(R¹¹)- or -S(O)_nO-;

A⁵ represents A⁷ or -S(O)_nO-;

A⁶ represents a single bond, -N(R¹¹)- or O-;

A⁷ represents a single bond, -C(Q²)-, -C(Q²)N(R¹¹)-, -C(Q²)O-, -S(O)_n- or -S(O)_nN(R¹¹);

Q¹ and Q² independently represent, on each occasion when mentioned above, =O, =S, =NR¹⁰, =NN(R¹⁰)(R¹¹), =NOR¹⁰, =NS(O)_nN(R¹⁰)(R¹¹), =NCN, =C(H)NO₂ or =C(R¹⁰)(R¹¹);

R⁶ and R⁷ independently represent, on each occasion when mentioned above:

I) hydrogen;

II) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B; or

III) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which groups are optionally substituted by one or more substituents selected from G² and/or Q³; or

A⁶ and R⁷ may be linked together to form along with the N atom and -E- group to which A⁶ and A⁷ are respectively attached, a 5- to a-membered ring, optionally containing 1 to 3

heteroatoms and/or 1 to 3 unsaturations, which ring is optionally substituted by one or more substituents selected from G² and/or Q³.

B represents:

I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G² and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁶, -OR⁶ and =O;

II) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G² and/or Q³, or

III) a G² group; or

IV) two adjacent B substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two B substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

G² represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A⁸-R¹²;

wherein A⁸ represents a single bond or a spacer group selected from -C(Q⁴)A⁹, -S(O)_nA¹⁰-, -N(R¹³)A¹¹-, -OA¹²- and -S-, in which;

A⁹ represents A¹³ or -S-;

A¹⁰ represents A¹³;

A¹¹ represents A¹⁴, -C(Q⁴)N(R¹³)C(Q⁴)N(R¹³)-, -C(Q⁴)N(R¹³)C(Q⁴)O-, -C(Q⁴)N(R¹³)S(O)_nN(R¹³)-, -C(Q⁴)S-, -S(O)_nN(R¹³)C(Q⁴)N(R¹³)-, -S(O)_nN(R¹³)C(Q⁴)O-, -S(O)_nN(R¹³)S(O)_nN(R¹³)- or -S(O)_nO-;

A¹² represents A¹⁴ or -S(O)_nO-;

A¹³ represents a single bond, -N(R¹³)- or -O-;

A¹⁴ represents a single bond, -C(Q⁴)-, -C(Q⁴)N(R¹³)-, -C(Q⁴)O-, -S(O)_n or -S(O)_nN(R¹³);

Q³ and Q⁴ independently represent, on each occasion when mentioned above, =O, =S, =NR¹², =NN(R¹²)(R¹³), =NOR¹², =NS(O)₂N(R¹²)(R¹³), =NCN, =C(H)NO₂ or =C(R¹²)(R¹³);

R⁶, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are independently selected from:

i) hydrogen;

ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G³ and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms, which ring is itself optionally substituted by one or more substituents selected from halo, -R¹⁴, -OR¹⁴ and =O; or

iii) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G³ and/or W¹; or

any pair of R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G³ and/or W¹;

G³ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹⁵-R¹⁵;

wherein A¹⁵ represents a single bond or a spacer group selected from -C(W²)A¹⁶-, -S(O)_nA¹⁷-, -N(R¹⁶)A¹⁸-, -OA¹⁹- and -S-, in which:

A¹⁶ represents A²⁰ or -S-;

A¹⁷ represents A²⁰;

A¹⁸ represents A²¹, -C(W²)N(R¹⁶)C(W²)N(R¹⁶)-, -C(W²)N(R¹⁶)C(W²)O-, -C(W²)N(R¹⁶)S(O)_nN(R¹⁶)-, -C(W²)S-, -S(O)_nN(R¹⁶)C(W²)N(R¹⁶)-, -S(O)_nN(R¹⁶)C(W²)O-, -S(O)_nN(R¹⁶)S(O)_nN(R¹⁶)- or -S(O)_nO-;

A¹⁹ represents A²¹ or -S(O)_nO-;

A²⁰ represents a single bond, -N(R¹⁶)- or -O-;

A²¹ represents a single bond, -C(W²)-, -C(W²)N(R¹⁶)-, -C(W²)O-, -S(O)_n- or -S(O)_nN(R¹⁶)-;

W¹ and W² independently represent, on each occasion when mentioned above, =O, =S, =NR¹⁵, =NN(R¹⁵)(R¹⁶), =NOR¹⁵, =NS(O)₂N(R¹⁵)(R¹⁶), =NCN, =C(H)NO₂ or =C(R¹⁵)(R¹⁶);

R¹⁴, R¹⁵ and R¹⁶ are independently selected from:

i) hydrogen;

ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G⁴, methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy; or

iii) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G⁴ and/or J; or

any pair of R¹⁴, R¹⁵ and R¹⁶ may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G⁴ and J;

G⁴ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A²²-R¹⁷,

wherein A²² represents a single bond or a spacer group selected from -C(O)A²³-, -S(O)_nA²⁴-, -N(R¹⁸)A²⁵-, -OA²⁶- and -S-, in which:

A²³ represents A²⁷ or -S-;

A²⁴ represents A²⁷.

A²⁵ represents A²⁸, -C(O)N(R¹⁸)C(O)N(R¹⁸)-, -C(O)N(R¹⁸)C(O)O-, -C(O)N(R¹⁸)S(O)_nN(R¹⁸)-, -C(O)S-, -S(O)_nN(R¹⁸)C(O)N(R¹⁸)-, -S(O)_nN(R¹⁸)C(O)O-, -S(O)_nN(R¹⁸)S(O)_nN(R¹⁸)- or -S(O)_nO-;

A²⁶ represents A²⁸ or -S(O)_nO-;

A²⁷ represents a single bond, -N(R¹⁸)- or -O-;

A²⁸ represents a single bond, -C(O)-, -C(O)N(R¹⁸)-, -C(O)O-, -S(O)_n- or -S(O)_nN(R¹⁸)-

J represents, on each occasion when mentioned above, =O, =S, =NR¹⁷, =NN(R¹⁷)(R¹⁸), =NOR¹⁷, =NS(O)_nN(R¹⁷)(R¹⁸), =NCN, =C(H)NO₂ or =C(R¹⁷)(R¹⁸);

R¹⁷ and R¹⁸ are independently selected from hydrogen and C'-6 alkyl, which latter group is optionally substituted by one or more substituents selected from halo, -NH₂, -N(H)Me, -N(H)Et, -N(H)j-Pr, -NMe₂, -N(Me)Et, -N(Me)j-Pr, -NEt₂, -OH, -OMe, -OEt, -Oj-, Pr and =O; and n represents, on each occasion when mentioned above, 1 or 2, or a pharmaceutically-acceptable salt thereof.

2. (currently amended): A compound as claimed in Claim 1, wherein;

X represents:

i) ~~an aryl group or a heteroaryl group, both of which groups are optionally substituted by one or more substituents selected from A; or~~

ii) $-N(R^6)-E-R^7$;

E represents a single bond, $-CG(O)-$ or $-S(O)_n-$;

Y represents $-CH_2OH$, $-C(O)N(H)R^6$, $-C(O)N(H)OR^6$ or $-C(O)OR^6$;

Z represents a C_{1-8} alkylene or a C_{2-8} heteroalkylene chain, both of which:

(i) optionally contain one or more unsaturations;

(ii) are optionally substituted by one or more substituents selected from halo, $-R^8$, $-N(R^6)(R^6)$, $-OR^8$ and $=O$; and/or

(iii) may form part of an additional 3- to a-membered ring formed between any one or more members of the $C1-S$ alkylene or $C2-S$ heteroalkylene chain, which ring optionally contains 1 to 3 heteroatoms and/or 1 to 3 unsaturations and which ring is itself optionally substituted by one or more substituents selected from halo, $-R^8$, $-N(R^6)(R^6)$, $-OR^8$ and $=O$;

R^1 represents an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from A;

one of the groups R^2 , R^3 , R^4 and R^5 represents an aryl group or a heteroaryl group (both of which are optionally substituted by one or more substituents selected from A) and:

a) the other groups are independently selected from hydrogen, G^1 , an aryl group, a heteroaryl group (which latter two groups are optionally substituted by one or more substituents selected from A), C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-8} heterocycloalkyl (which latter five groups are optionally substituted by one or more substituents selected from G^1 and/or Q^1); and/or

b) any two other groups which are adjacent to each other are optionally linked to form, along with two atoms of the essential benzene ring in the compound of formula I, a 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, $-R^8$, $-OR^8$ and $=O$;

A represents, ~~on each occasion when mentioned above:~~

l) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B;

II) a C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-8} heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G^1 and/or Q^1 ; or

III) a G^1 group; or

IV) two adjacent A substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two A substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, $-R^8$, $-OR^8$ and $=O$;

G^1 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^1-R^{10}$;

wherein A^1 represents a single bond or a spacer group selected from $-C(Q^2)A^2-$, $-S(O)_nA^3-$, $-N(R^{11})A^4-$, $-OA^5-$ and $-S-$, in which:

A^2 represents A^6 or $-S-$;

A^3 represents A^6 ;

A^4 represents A^7 , $-C(Q^2)N(A^{11})C(Q^2)N(R^{11})-$, $-C(Q^2)N(A^{11})C(Q^2)O-$, $C(Q^2)N(A^{11})S(O)_nN(R^{11})-$, $-C(Q^2)S-$, $-S(O)_nN(R^{11})C(Q^2)N(R^{11})-$, $-S(O)_nN(R^{11})C(Q^2)O-$, $-S(O)_nN(R^{11})S(O)_nN(R^{11})-$ or $-S(O)_nO-$;

A^5 represents A^7 or $-S(O)_nO-$;

A^6 represents a single bond, $-N(R^{11})-$ or $O-$;

A^7 represents a single bond, $-C(Q^2)-$, $-C(Q^2)N(R^{11})-$, $-C(Q^2)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{11})$;

Q^1 and Q^2 independently represent, on each occasion when mentioned above, $=O$, $=S$, $=NR^{10}$, $=NN(R^{10})(R^{11})$, $=NOR^{10}$, $=NS(O)_2N(R^{10})(R^{11})$, $=NCN$, $=C(H)NO_2$ or $=C(R^{10})(R^{11})$;

R^6 and R^7 independently represent, on each occasion when mentioned above:

I) hydrogen;

II) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B; or

III) a C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-8} heterocycloalkyl group, all of which groups are optionally substituted by one or more substituents selected from G^2 and/or Q^3 ; or

A^6 and R^7 may be linked together to form along with the N atom and $-E-$ group to which A^6 and A^7 are respectively attached, a 5- to a-membered ring, optionally containing 1 to 3

heteroatoms and/or 1 to 3 unsaturations, which ring is optionally substituted by one or more substituents selected from G^2 and/or Q^3 ;

B represents, on each occasion when mentioned above:

- I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^2 and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, $-R^8$, $-OR^8$ and $=O$;
- II) a C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-8} heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G^2 and/or Q^3 ; or
- III) a G^2 group; or
- IV) two adjacent B substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two B substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, $-R^8$, $-OR^8$ and $=O$;

G^2 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^8-R^{12}$;

wherein A^8 represents a single bond or a spacer group selected from $-C(Q^4)A^9$, $-S(O)_nA^{10}$, $-N(R^{13})A^{11}$, $-OA^{12}$ and $-S-$, in which:

A^9 represents A^{13} or $-S-$;

A^{10} represents A^{13} ;

A^{11} represents A^{14} , $-C(Q^4)N(R^{13})C(Q^4)N(R^{13})-$, $-C(Q^4)N(R^{13})C(Q^4)O-$,

$-C(Q^4)N(R^{13})S(O)_nN(R^{13})-$, $-C(Q^4)S-$, $-S(O)_nN(R^{13})C(Q^4)N(R^{13})-$, $-S(O)_nN(R^{13})C(Q^4)O-$,

$-S(O)_nN(R^{13})S(O)_nN(R^{13})-$ or $-S(O)_nO-$;

A^{12} represents A^{14} or $-S(O)_nO-$;

A^{13} represents a single bond, $-N(R^{13})-$ or $-O-$;

A^{14} represents a single bond, $-C(Q^4)-$, $-C(Q^4)N(R^{13})-$, $-C(Q^4)O-$, $-S(O)_n$ or $-S(O)_nN(R^{13})$;

Q^3 and Q^4 independently represent, on each occasion when mentioned above, $=O$, $=S$, $=NR^{12}$, $=NN(R^{12})(R^{13})$, $=NOR^{12}$, $=NS(O)_2N(R^{12})(R^{13})$, $=NCN$, $=C(H)NO_2$ or $=C(R^{12})(R^{13})$;

R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} are independently selected from:

- i) hydrogen;

ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^3 and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms, which ring is itself optionally substituted by one or more substituents selected from halo, $-R^{14}$, $-OR^{14}$ and $=O$; or

iii) a C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-8} heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G^3 and/or W^1 ; or

any pair of R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{13} may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G^3 and/or W^1 ;

G^3 represents, on each occasion when mentioned above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^{15}$, $-R^{15}$;

wherein A^{15} represents a single bond or a spacer group selected from $-C(W^2)A^{16}$, $-S(O)_nA^{17}$, $-N(R^{16})A^{18}$, $-OA^{19}$ and $-S-$, in which:

A^{16} represents A^{20} or $-S-$;

A^{17} represents A^{20} ;

A^{18} represents A^{21} , $-C(W^2)N(R^{16})C(W^2)N(R^{16})-$, $-C(W^2)N(R^{16})C(W^2)O-$, $-C(W^2)N(R^{16})S(O)_nN(R^{16})-$, $-C(W^2)S-$, $-S(O)_nN(R^{16})C(W^2)N(R^{16})-$, $-S(O)_nN(R^{16})C(W^2)O-$, $-S(O)_nN(R^{16})S(O)_nN(R^{16})-$ or $-S(O)_nO-$;

A^{19} represents A^{21} or $-S(O)_nO-$;

A^{20} represents a single bond, $-N(R^{16})-$ or $-O-$;

A^{21} represents a single bond, $-C(W^2)-$, $-C(W^2)N(R^{16})-$, $-C(W^2)O-$, $-S(O)_n-$ or $-S(O)_nN(R^{16})-$;

W^1 and W^2 independently represent, on each occasion when mentioned above, $=O$, $=S$, $=NR^{15}$, $=NN(R^{15})(R^{16})$, $=NOR^{15}$, $=NS(O)_2N(R^{15})(R^{16})$, $=NCN$, $=C(H)NO_2$ or $=C(R^{15})(R^{16})$;

R^{14} , R^{15} and R^{16} are independently selected from:

- i) hydrogen;
- ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^4 , methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy; or

iii) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G⁴ and/or J; or

any pair of R¹⁴, R¹⁵ and R¹⁶ may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G⁴ and J;

G⁴ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A²²-R¹⁷;

wherein A²² represents a single bond or a spacer group selected from -C(O)A²³-, -S(O)_nA²⁴-, -N(R¹⁸)A²⁵-, -OA²⁶- and -S-, in which:

A²³ represents A²⁷ or -S-;

A²⁴ represents A²⁷;

A²⁵ represents A²⁸, -C(O)N(R¹⁸)C(O)N(R¹⁸)-, -C(O)N(R¹⁸)C(O)O-, -C(O)N(R¹⁸)S(O)_nN(R¹⁸)-, -C(O)S-, -S(O)_nN(R¹⁸)C(O)N(R¹⁸)-, -S(O)_nN(R¹⁸)C(O)O-, -S(O)_nN(R¹⁸)S(O)_nN(R¹⁸)- or -S(O)_nO-;

A²⁶ represents A²⁸ or -S(O)_nO-;

A²⁷ represents a single bond, -N(R¹⁸)- or -O-;

A²⁸ represents a single bond, -C(O)-, -C(O)N(R¹⁸)-, -C(O)O-, -S(O)_n- or -S(O)_nN(R¹⁸)

J represents, on each occasion when mentioned above, =O, =S, =NR¹⁷, =NN(R¹⁷)(R¹⁸), =NOR¹⁷, =NS(O)₂N(R¹⁷)(R¹⁸), =NCN, =C(H)NO₂ or =C(R¹⁷)(R¹⁸);

R¹⁷ and R¹⁸ are independently selected from hydrogen and C¹-6 alkyl, which latter group is optionally substituted by one or more substituents selected from halo, -NH₂, -N(H)Me, -N(H)Et, -N(H)-i-Pr, -NMe₂, -N(Me)Et, -N(Me)-i-Pr, -NEt₂, -OH, -OMe, -OEt, -O-i-Pr and =O; and n represents, on each occasion when mentioned above, 1 or 2, or a pharmaceutically-acceptable salt thereof.

3. (original): A compound as claimed in Claim 2, wherein n represents 2.
4. (previously presented): A compound as claimed in Claim 2, wherein A represents G^1 or any two adjacent A substituents may be linked by a methylenedioxy group.
5. (previously presented): A compound as claimed in claim 2, wherein G^1 represents halo, cyano, $-NO_2$ or $-A^1-R^{10}$.
6. (previously presented): A compound as claimed in claim 2, wherein A^2 represents A^6 .
7. (previously presented): A compound as claimed in claim 2, wherein A^3 and A^5 independently represent a single bond.
8. (previously presented): A compound as claimed in claim 2, wherein A^4 represents a single bond, $-C(Q^2)-$ or $-S(O)_2-$.
9. (previously presented): A compound as claimed in claim 2, wherein Q^2 represents $=O$.
10. (previously presented): A compound as claimed in claim 2, wherein B represents G^2 .
11. (previously presented): A compound as claimed in claim 2, wherein G^2 represents halo, cyano, $-NO_2-$ or $-A^8-R^{12}$.
12. (previously presented): A compound as claimed in claim 2, wherein A^8 represents a single bond, $-N(R^{13})A^{11}-$ or $-OA^{12}-$.
13. (previously presented): A compound as claimed in claim 2, wherein A^{11} and A^{12} independently represent a single bond.

14. (previously presented): A compound as claimed in claim 1, wherein Z represents C₁₋₆ alkylene, in which one of the carbon atoms in the chain may be replaced with oxygen.

15. (previously presented): A compound as claimed in claim 1, wherein Y represents –CH₂OH, –C(O)NHR⁵ or –C(O)OR⁵.

16. (previously presented): A compound as claimed in claim 1, wherein R¹ represents optionally substituted fluorenyl, phenyl or pyridyl.

17. (previously presented): A compound as claimed in claim 1, wherein (when X represents an optionally substituted aryl or heteroaryl group) X represents an optionally substituted phenyl, thienyl, pyridyl, pyrazolyl, pyrazinyl or quinolinyl group.

18. (previously presented): A compound as claimed in claim 1, (when they represent an optionally substituted aryl or heteroaryl group) R², R³, R⁴, and R⁵ represent optionally substituted phenyl, pyridyl or naphthyl.

19. (currently amended): A compound as claimed in Claim 28 2, wherein the other substituents on the benzene ring of the indole represent hydrogen or G¹.

20. (previously presented): A compound as claimed in claim 2, wherein R⁶ represents hydrogen or C₁₋₃ alkyl group (which latter group is optionally substituted by G²).

21. (previously presented): A compound as claimed in claim 2, wherein R⁷ represents phenyl or pyridyl (which groups are optionally substituted by one or more substituents selected from B), or C₁₋₄ alkyl, C₂₋₄ alkenyl or C₅₋₁₀ cycloalkyl (which latter three groups are optionally substituted by one or more substituents selected from G²).

22. (previously presented): A compound as claimed in claim 2, wherein R⁶ and R⁷ are linked to form a 5- or 6-membered ring optionally substituted by =O.

23. (previously presented): A compound as claimed in Claim 2, wherein R⁸ and R¹³ independently represent C₁₋₃ alkyl or hydrogen.

24. (previously presented): A compound as claimed in claim 2, wherein R^{10} represents hydrogen, phenyl, tetrazolyl, C_{1-4} alkyl, C_{2-4} alkenyl or C_{5-6} cycloalkyl, which latter five groups are optionally substituted by one or more substituents selected from G^3 .

25. (previously presented): A compound as claimed in claim 2, wherein R^{12} represents hydrogen, phenyl, pyrrolyl, C_{1-4} alkyl or C_{5-10} cycloalkyl, which latter four groups are optionally substituted by one or more substituents selected from G^3 .

26. (previously presented): A compound as claimed in claim 2, wherein R^{11} represents hydrogen or C_{2-4} alkenyl.

27. (previously presented): A compound as claimed in claim 2, wherein G^3 represents halo, $-R^{15}$ or $-OR^{15}$.

28. (previously presented): A compound as claimed in claim 2, wherein R^{15} represents hydrogen, C_{1-3} alkyl or phenyl.

29. (previously presented): A compound as claimed in claim 16, wherein the optional substituents are selected from halo, $-NO_2$, cyano, methylenedioxy, C_{1-6} alkyl (which alkyl group is optionally substituted by one or more substituents selected from a halo group, a phenyl groups and OR^{19}), C_{2-6} alkenyl, C_{3-10} cycloalkyl (which cycloalkyl group is optionally substituted with C_{1-6} alkyl), phenyl (which group is optionally substituted with one or more substituents selected from halo and OR^{19}), a heteroaryl group selected from tetrazolyl and pyrrolyl (which groups are optionally substituted by one or more C_{1-6} alkyl groups), methylthio, methylsulfonyl, methylsulfonyl, $=O$, $-OR^{19}$, $-N(R^{19})R^{20}$, $-C(O)OR^{19}$, $-C(O)R^{19}$, $-C(O)N(R^{19})R^{20}$, $-S(O)_2N(R^{19})R^{20}$ and/or $-N(R^{19})S(O)_2R^{21}$, wherein R^{19} and R^{20} independently represent hydrogen, phenyl, C_{1-4} alkenyl, C_{1-6} alkyl (which alkyl group is optionally substituted by one or more fluoro atoms) or a phenyl group and R^{21} represents phenyl or C_{1-6} alkyl (which alkyl group is optionally substituted by one or more fluoro atoms).

30. (previously presented): A compound as defined in claim 1, or a pharmaceutically-acceptable salt thereof, for use as a pharmaceutical.

31. (previously presented): A pharmaceutical formulation including a compound as defined in claim 1, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

32. (currently amended): A method for the ~~treatment of a disease in which~~ inhibition of the activity of microsomal prostaglandin E synthase-1 ~~is desired and/or required~~ which comprises administering to a host in need of such ~~treatment~~ inhibition an effective amount of a compound as defined in claim 1, or a pharmaceutically-acceptable salt thereof.

33. (currently amended): A method as claimed in Claim 32, wherein the ~~disease is~~ inhibition is directed towards inflammation.

34. (canceled)

35. (currently amended): A method ~~of treatment of a disease in which~~ for inhibition of the activity of mPGES-1 ~~is desired and/or required~~, which method comprises administration of ~~a therapeutically an~~ effective amount of a compound as defined in claim 1, or a pharmaceutically-acceptable salt thereof, to ~~a patient suffering from, or susceptible to, such a condition~~ host requiring such inhibition.

36. (previously presented): A combination product comprising:

(A) a compound as defined in claim 1, or a pharmaceutically-acceptable salt thereof,
and

(B) another therapeutic agent that is useful in the treatment of inflammation, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

37. (currently amended): A combination product as claimed in Claim 36 which comprises a pharmaceutical formulation including a compound as defined ~~above~~ in Claim 1, or a pharmaceutically-acceptable salt thereof, another therapeutic agent that is useful in the treatment of inflammation, and a pharmaceutically-acceptable adjuvant, diluent or carrier.

38. (currently amended): A combination product as claimed in Claim 36 which comprises a kit of parts comprising components:

(a) a pharmaceutical formulation including a compound as defined above in Claim 1, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of inflammation in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,


which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

adjuvant, diluent or carrier,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

39. (original): A process for the preparation of a compound as defined in Claim 2, which comprises:

(i) reaction of a compound of formula II,




wherein X, Y, R², R³, R⁴ and R⁵ are as defined in Claim 2, with a compound of formula III,



wherein L¹ represents a suitable leaving group and R¹ and Z are as defined in Claim 2;

(ii) reaction of a compound of formula IV,




wherein L^4 represents L^2 or L^3 , in which L^2 and L^3 represent appropriate leaving groups and L^4 is attached to one or more of the carbon atoms of the benzenoid ring of the indole, and the remaining positions of the benzenoid ring are substituted with 1 to 3 (depending on the number of L^4 substituents) substituents R^2 to R^6 as appropriate, and Z, X, Y, R^1 , R^2 , R^3 , R^4 and R^5 are as defined in Claim 2, with a compound of formula V,



wherein R^{22} represents R^2 , R^3 , R^4 or R^5 (as appropriate), and L^5 represents L^2 (when L^4 is L^3) or L^3 (when L^4 is L^2) as defined above;

(iii) for compounds of formula I in which X represents an optionally substituted aryl or heteroaryl group, reaction of a compound of formula VI,



wherein L^2 is as defined above and Z, Y, R^1 , R^2 , R^3 , R^4 and R^5 are as defined in Claim 2, with a compound of formula VII,




wherein L^3 is as defined above and X^a represents an aryl or heteroaryl group, optionally substituted as defined in Claim 2;

(iv) for compounds of formula I in which X represents $-N(R^6)-E-R^7$, reaction of a compound of formula VI as defined above, with a compound of formula VIII,



wherein E, R^6 and R^7 are as defined in Claim 2;

(v) for compounds of formula I in which X represents $-N(R^6)-E-R^7$, reaction of a compound of formula IX,




wherein Z, Y, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in Claim 2, with a compound of formula X,



wherein L¹ is as defined above and E and R⁺ are as defined in Claim 2;

(vi) for compounds of formula I in which E represents a single bond and R⁷ is a C₁₋₆ alkyl group, C₃₋₆ alkenyl or a C₃₋₆ alkynyl group, reduction of a compound of formula I, wherein X represents -C(O)- and R⁷ represents H, a C₁₋₆ alkyl group, a C₂₋₅ alkenyl or a C₂₋₅ alkynyl group.

40. (currently amended): A compound of formula I,



wherein X represents an optionally substituted amide, amine or sulfonamide group, wherein said groups are connected to the indole ring through their nitrogen atom;

Y represents a carboxylic acid, a carboxylic acid ester, a carboxylic acid amide, a hydroxamic acid, a hydroxamic acid ester or hydroxymethyl;

Z represents a spacer group comprises a C₁₋₈ alkylene or a C₂₋₈ heteroalkylene group;

R¹ represents an optionally substituted aryl or heteroaryl group;

one of the groups R², R³, R⁴ and R⁵ represents an optionally substituted aryl or heteroaryl group and the other groups R², R³, R⁴ and R⁵ are independently selected from hydrogen, G¹, an aryl group, a heteroaryl group (which latter two groups are optionally substituted by one or more substituents selected from A), C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₆ heterocycloalkyl (which latter five groups are optionally substituted by one or more substituents selected from G¹ and/or Q¹); and/or

b) any two other groups which are adjacent to each other are optionally linked to form, along with two atoms of the essential benzene ring in the compound of formula I, a 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

A represents:

I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B;

II) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G¹ and/or Q¹, or

III) a G¹ group; or

IV) two adjacent A substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two A substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

G¹ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹-R¹⁰,

wherein A¹ represents a single bond or a spacer group selected from -C(Q²)A²-, -S(O)_nA³-, -N(R¹¹)A⁴-, -OA⁵- and -S-, in which:

A² represents A⁶ or -S-;

A³ represents A⁶;

A⁴ represents A⁷, -C(Q²)N(A¹¹)C(Q²)N(R¹¹)-, -C(Q²)N(A¹¹)C(Q²)O-, C(Q²)N(A¹¹)S(O)_nN(R¹¹)-, -C(Q²)S-, -S(O)_nN(R¹¹)C(Q²)N(R¹¹)-, -S(O)_nN(R¹¹)C(Q²)O-, -S(O)_nN(R¹¹)S(O)_nN(R¹¹)- or -S(O)nO-;

A⁵ represents A⁷ or -S(O)_nO-;

A⁶ represents a single bond, -N(R¹¹)- or O-;

A⁷ represents a single bond, -C(Q²)-, -C(Q²)N(R¹¹)-, -C(Q²)O-, -S(O)_n- or -S(O)_nN(R¹¹);

Q¹ and Q² independently represent, on each occasion when mentioned above, =O, =S, =NR¹⁰, =NN(R¹⁰)(R¹¹), =NOR¹⁰, =NS(O)₂N(R¹⁰)(R¹¹), =NCN, =C(H)NO₂ or =C(R¹⁰)(R¹¹);

R⁶ and R⁷ independently represent, on each occasion when mentioned above:

I) hydrogen;

II) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from B; or

III) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which groups are optionally substituted by one or more substituents selected from G² and/or Q³, or

A⁶ and R⁷ may be linked together to form along with the N atom and -E- group to which A⁶ and A⁷ are respectively attached, a 5- to a-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is optionally substituted by one or more substituents selected from G² and/or Q³.

B represents:

I) an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G² and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

II) a C₁₋₅ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G² and/or Q³, or

III) a G² group; or

IV) two adjacent B substituents may be linked together to form, along with the essential atoms of the aryl or heteroaryl group to which the two B substituents are attached, a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from halo, -R⁸, -OR⁸ and =O;

G² represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A⁸-R¹²;

wherein A⁸ represents a single bond or a spacer group selected from -C(Q⁴)A⁹, -S(O)_nA¹⁰, -N(R¹³)A¹¹, -OA¹² and -S-, in which:

A⁹ represents A¹³ or -S-;

A¹⁰ represents A¹³;

A¹¹ represents A¹⁴, -C(Q⁴)N(R¹³)C(Q⁴)N(R¹³), -C(Q⁴)N(R¹³)C(Q⁴)O-, -C(Q⁴)N(R¹³)S(O)_nN(R¹³), -C(Q⁴)S-, -S(O)_nN(R¹³)C(Q⁴)N(R¹³), -S(O)_nN(R¹³)C(Q⁴)O-, -S(O)_nN(R¹³)S(O)_nN(R¹³)- or -S(O)_nO-;

A¹² represents A¹⁴ or -S(O)_nO-;

A¹³ represents a single bond, -N(R¹³)- or -O-;

A¹⁴ represents a single bond, -C(Q⁴), -C(Q⁴)N(R¹³), -C(Q⁴)O-, -S(O)_n or -S(O)_nN(R¹³);

Q³ and Q⁴ independently represent, on each occasion when mentioned above, =O, =S, =NR¹², =NN(R¹²)(R¹³), =NOR¹², =NS(O)_nN(R¹²)(R¹³), =NCN, =C(H)NO₂ or =C(R¹²)(R¹³).

R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ are independently selected from:

i) hydrogen;

ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G³ and/or wherein any two adjacent atoms of the aryl or heteroaryl group may be linked together to form a further 5- to 6-membered ring, optionally containing 1 or more heteroatoms, which ring is itself optionally substituted by one or more substituents selected from halo, -R¹⁴, -OR¹⁴ and =O; or

iii) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G³ and/or W¹; or

any pair of R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³ may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 8-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G³ and/or W¹.

G³ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹⁵-R¹⁵.

wherein A¹⁵ represents a single bond or a spacer group selected from -C(W²)A¹⁶-, -S(O)_nA¹⁷-, -N(R¹⁶)A¹⁸-, -OA¹⁹- and -S-, in which:

A¹⁶ represents A²⁰ or -S-;

A¹⁷ represents A²⁰;

A¹⁸ represents A²¹, -C(W²)N(R¹⁶)C(W²)N(R¹⁶)-, -C(W²)N(R¹⁶)C(W²)O-, -C(W²)N(R¹⁶)S(O)_nN(R¹⁶)-, -C(W²)S-, -S(O)_nN(R¹⁶)C(W²)N(R¹⁶)-, -S(O)_nN(R¹⁶)C(W²)O-, -S(O)_nN(R¹⁶)S(O)_nN(R¹⁶)- or -S(O)_nO-;

A¹⁹ represents A²¹ or -S(O)_nO-;

A²⁰ represents a single bond, -N(R¹⁶)- or -O-;

A²¹ represents a single bond, -C(W²)-, -C(W²)N(R¹⁶)-, -C(W²)O-, -S(O)_n- or -S(O)_nN(R¹⁶);

W¹ and W² independently represent, on each occasion when mentioned above, =O, =S, =NR¹⁵, =NN(R¹⁵)(R¹⁶), =NOR¹⁵, =NS(O)_nN(R¹⁵)(R¹⁶), =NCN, =C(H)NO₂ or =C(R¹⁵)(R¹⁶);

R¹⁴, R¹⁵ and R¹⁶ are independently selected from:

i) hydrogen;

ii) an aryl or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G⁴, methylenedioxy, difluoromethylenedioxy and/or dimethylmethylenedioxy; or

iii) a C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl or C₃₋₈ heterocycloalkyl group, all of which are optionally substituted by one or more substituents selected from G⁴ and/or J; or

any pair of R¹⁴, R¹⁵ and R¹⁶ may, for example when present on the same or on adjacent atoms, be linked together to form with those, or other relevant, atoms, a further 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 unsaturations, which ring is itself optionally substituted by one or more substituents selected from G⁴ and J;

G⁴ represents, on each occasion when mentioned above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A²²-R¹⁷;

wherein A²² represents a single bond or a spacer group selected from -C(O)A²³-, -S(O)_nA²⁴-, -N(R¹⁸)A²⁵-, -OA²⁶- and -S-, in which:

A²³ represents A²⁷ or -S-;

A²⁴ represents A²⁷;

A²⁵ represents A²⁸, -C(O)N(R¹⁸)C(O)N(R¹⁸)-, -C(O)N(R¹⁸)C(O)O-, -C(O)N(R¹⁸)S(O)_nN(R¹⁸)-, -C(O)S-, -S(O)_nN(R¹⁸)C(O)N(R¹⁸)-, -S(O)_nN(R¹⁸)C(O)O-, -S(O)_nN(R¹⁸)S(O)_nN(R¹⁸)- or -S(O)_nO-;

A²⁶ represents A²⁸ or -S(O)_nO-;

A²⁷ represents a single bond, -N(R¹⁸)- or -O-;

A²⁸ represents a single bond, -C(O)-, -C(O)N(R¹⁸)-, -C(O)O-, -S(O)_n- or -S(O)_nN(R¹⁸)-

J represents, on each occasion when mentioned above, =O, =S, =NR¹⁷, =NN(R¹⁷)(R¹⁸), =NOR¹⁷, =NS(O)₂N(R¹⁷)(R¹⁸), =NCN, =C(H)NO₂ or =C(R¹⁷)(R¹⁸);

R¹⁷ and R¹⁸ are independently selected from hydrogen and C'-6 alkyl, which latter group is optionally substituted by one or more substituents selected from halo, -NH₂, -N(H)Me, -N(H)Et, -N(H)i-Pr, -NMe₂, -N(Me)Et, -N(Me)i-Pr, -NEt₂, -OH, -OMe, -OEt, -Oi-, Pr and =O; and
n represents, on each occasion when mentioned above, 1 or 2,
or a pharmaceutically-acceptable salt thereof.

41. (currently amended): A compound according to claim 40 wherein

X is a substituted benzoylamino group;

Y is a carboxylic acid or carboxylic acid ester group;

Z is alkylene represents an optionally substituted C₁₋₈ alkylene or a C₂₋₉ heteroalkylene group;

R¹ is an optionally substituted aryl group;

one of R², R³, R⁴ and R⁵ is optionally substituted aryl and the others are hydrogen.

42. (previously presented): A compound according to claim 41 which is 6-(4-butylphenyl)-1-(3-chlorobenzyl)-3-(4-isopropoxybenzoylamino)-indole-2-carboxylic acid.